This inventor holds 1 USPTO granted patent. Top assignee: Amgen Inc.. Active years: 2010.
Company Filing History:
Years Active: 2010
Title: Melissa Coughlin: Innovator in Antibody Development
Introduction
Melissa Coughlin is a prominent inventor based in Chicago, IL (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting the SARS coronavirus. Her innovative work has implications for both diagnosis and treatment of viral infections.
Latest Patents
Melissa Coughlin holds a patent for "Antibodies to SARS coronavirus." This invention relates to antibodies, including human antibodies and antigen-binding portions that specifically bind to the human SARS-CoV S protein. These antibodies function to neutralize SARS-CoV. The patent also covers bispecific antibodies, derivatized antibodies, single-chain antibodies, and portions of fusion proteins. Additionally, it includes isolated heavy and light chain immunoglobulins derived from human anti-SARS-CoV S protein antibodies, along with nucleic acid molecules encoding such immunoglobulins. The invention outlines methods for using these antibodies and compositions for diagnosis and treatment, as well as gene therapy methods utilizing nucleic acid molecules encoding the immunoglobulin molecules. Furthermore, it discusses transgenic animals or plants that incorporate the nucleic acid molecules of the invention.
Career Highlights
Melissa Coughlin is associated with Amgen Inc., a leading biotechnology company. Her work at Amgen has allowed her to collaborate with other experts in the field, enhancing the impact of her research and innovations.
Collaborations
Some of her notable coworkers include John Stephen Babcook and Bellur S Prabhakar. Their collaborative efforts contribute to the advancement of biotechnology and the development of effective treatments for viral infections.
Conclusion
Melissa Coughlin's innovative work in antibody development showcases her significant contributions to biotechnology. Her patent on antibodies to SARS coronavirus highlights the potential for advancements in diagnosis and treatment of viral diseases.